In 2021, the epigenetics industry was worth around USD 1,563.8 million, and it is projected to advance at a 17.1% CAGR from 2021 to 2030, hitting USD 6,460.5 million by 2030, according to P&S Intelligence.
The fast technological expansions and their real-time acceptance by end users have formed profitable opportunities for key businesses within the whole molecular diagnostics biosphere. The diagnostics and biotech industries are swiftly developing to regularize epigenetics in medical settings, with both industry giants and developing, disruptive businesses playing a vital role.
In 2021, the kits, assays, and reagents category generated the largest revenue share of 60% in the market. This growth can be credited to the low-cost, fast growth of simple-to-use and advanced epigenetics kits and reagents.
In 2021, North America held the largest epigenetics market revenue share. This dominance can be credited to the existence of better healthcare infrastructure and well-known businesses pursuing research and development in epigenetics, increasing count of cancer cases, and growing acceptance of items based on advanced molecular technologies by pharmacological and biotechnological businesses.
In the past few years, Europe had the second-largest share, of above 25%, mainly because of the absolute surge in the frequency of chronic illnesses that demand precise diagnosis.
Numerous European nations, such as the U.K., Germany, Spain, the U.K., France, and Italy are working hard to advance research initiatives to such extents. Additionally, because of the high investment, the region has always been at the front of research to improve diagnostics on a worldwide level.
Hence, Epigenetics is the study of how behavior and the environment affect genetic working.